Introduction
============

The inward rectifier family of potassium (Kir) channels is comprised of at least 16 family members exhibiting unique functional and regulatory properties that enable them to carry out important functions in most organ systems (Hebert et al., [@B15]; Hibino et al., [@B17]). Kir channels preferentially pass current in the inward direction at voltages more negative than the Nernst electrochemical equilibrium potential for potassium (*E*~K~). Unlike their voltage-gated potassium channel counterparts, Kir channels lack discrete voltage-sensing domains that regulate pore opening. Rather, the rectification of the channel conductance-voltage relationship is due to voltage-dependent pore block by magnesium and polyamines at potentials more positive than *E*~K~. The degree of rectification varies widely between family members and is used to categorize them functionally into groups of strong versus weak rectifiers. In general, strong rectifiers are expressed in excitable cells such as neurons and muscle cells, whereas weak rectifiers are expressed in epithelial and other non-excitable cell types (Hibino et al., [@B17]). Some Kir channels are postulated therapeutic targets for common diseases (Bhave et al., [@B2]). Consequently, we have been working to develop small-molecule probes of clinically relevant Kir channels to provide sharper pharmacological tools with which to study their physiological roles and therapeutic potential.

The founding Kir channel family member Kir1.1, is a weak rectifier encoded by the gene *KCNJ1* (Ho et al., [@B18]; Zhou et al., [@B58]). Kir1.1 is expressed almost exclusively in epithelial cells of the renal tubule where it critically regulates salt and water balance and hence blood volume and pressure (Welling and Ho, [@B55]). Autosomal recessive mutations in *KCNJ1* give rise to antenatal Bartter syndrome, a severe salt and water wasting disorder characterized by hypokalemic metabolic alkalosis and low to normal blood pressure (Simon et al., [@B46]). In contrast, heterozygous carriers of *KCNJ1* mutations have lower blood pressure but no overt evidence of disease (Ji et al., [@B20]). These genetic data raise the intriguing possibility that Kir1.1 represents a drug target for a novel class of diuretic. Consequently, our group recently employed high-throughput screening and medicinal chemistry to develop the first publicly disclosed small-molecule inhibitors of Kir1.1 (Lewis et al., [@B26]; Bhave et al., [@B1]). These, as well as inhibitors recently disclosed by investigators at Merck (Pasternak et al., [@B38]), should be instrumental in assessing the therapeutic potential of Kir1.1 for the management of hypertension.

Another emerging drug target in the Kir channel family is the G protein-coupled inward rectifier potassium (GIRK) channel, which is expressed in the heart and throughout the nervous system (Hibino et al., [@B17]). The major cardiac form of GIRK is a heterotetrameric channel comprised of Kir3.1 and Kir3.4 subunits, which is expressed primarily in atrial but not ventricular myocytes. In the nervous system, heteromeric GIRK channels are primarily formed by Kir3.1 and Kir3.2. In the basal state, GIRK channels exhibit a low open-state probability and therefore contribute little to the resting membrane potassium conductance and potential. In the heart, sympathetic release of acetylcholine (ACh) onto M2 muscarinic receptors leads to G protein-dependent opening of GIRK channels, potassium efflux, and consequent membrane hyperpolarization. The ACh-induced increase in potassium conductance slows the rate of membrane depolarization, action potential generation, and heart rate. In patients with chronic atrial fibrillation, GIRK channels become constitutively active in atrial cardiomyocytes through mechanisms that are incompletely understood (Dobrev et al., [@B10]; Voigt et al., [@B50]; Makary et al., [@B31]). This background current hyperpolarizes the membrane potential, abbreviates the action potential, and increases the availability sodium channels for activation. A growing body of experimental and clinical data support the notion that electrical remodeling sets up high-frequency re-entrant current sources that perpetuate atrial fibrillation, suggesting that a specific blocker of GIRK could have anti-arrhythmic actions without the ventricular side effects commonly associated with current therapies (reviewed in Wakili et al., [@B51]). Similarly, the other Kir channel family member Kir2.3 is enriched in atrial cardiomyocytes and may also be a pharmaceutical target for atrial fibrillation (Ehrlich, [@B11]).

The molecular pharmacology of GIRK and most other inward rectifiers is limited. A high-throughput screen using a voltage-sensitive dye identified analogs of amiloride (a K^+^ sparing diuretic) and propafenone (a class 1c anti-arrhythmic) that inhibit GIRK with sub-micromolar potencies (Walsh, [@B52]). These and several cardiac and neurological drugs exhibiting weak off-target activity toward GIRK (reviewed in Bhave et al., [@B2]) may be useful lead compounds for developing more specific inhibitors of GIRK. The bee venom toxin tertiapin is a nanomolar affinity GIRK antagonist that also inhibits Kir1.1 (Jin and Lu, [@B21]; Kitamura et al., [@B22]). Hashimoto et al. ([@B14]) demonstrated that administration of tertiapin to cannulated dogs terminated induced atrial fibrillation, providing some of the first experimental evidence that GIRK is a target for anti-arrhythmic therapeutics (Hashimoto et al., [@B14]). Nissan Chemical Industries developed a benzopyrene derivative, termed NIP-142, which inhibits Kir3.1/3.4 GIRK channels with sub-micromolar affinity and the cardiac Kv1.5 delayed rectifier current with equal potency (Matsuda et al., [@B32]; Tanaka and Hashimoto, [@B47]). NIP-142 has shown efficacy in terminating induced atrial fibrillation in dogs, but it is unknown whether the improvement in sinus rhythm is due to inhibition of GIRK, Kv1.5, or both. However, the low nanomolar inhibitor NTC-801, which is highly selective for GIRK over other cardiac channels, was shown recently to be effective in several models of atrial fibrillation (Machida et al., [@B30]).

In an effort to further expand the molecular pharmacology of GIRK, we employed a Tl^+^ flux-based fluorescence assay to screen a Kir1.1 inhibitor focus library for antagonists of GIRK. One compound termed VU573 was found to preferentially inhibit GIRK (cardiac and neuronal forms), Kir2.3 and Kir7.1 over Kir1.1 and Kir2.1. We anticipate that VU573 and its analogs will be useful for investigating the physiology and structure--function relationships of inward rectifier potassium channels.

Materials and Methods {#s1}
=====================

Expression vectors
------------------

Plasmids used in this study are from the following sources: rat Kir1.1 (NM_017023; Chun Jiang, Georgia State University, Atlanta, GA, USA), human Kir2.1 (NM_000891.2; Al George, Vanderbilt University School of Medicine, Nashville, TN, USA), human Kir7.1 (NM_002242.2; David Clapham, Harvard Medical School, Cambridge, MA, USA). Human Kir1.1 (NM_000220), Kir3.1 (NM_002239.2), Kir3.2 (NM_002240.2), Kir3.4 (NM_000890.3), and Kir2.3 (NM_152868) were purchased from OriGene Technologies (Rockville, MD, USA). The M125R mutant of Kir7.1 was created using the QuickChange Site-Directed Mutagenesis Kit (Agilent Technologies). The open reading frame of Kir7.1 was fully sequenced to ensure that no spurious mutations were introduced during mutation of the intended codon.

Cell lines
----------

Monoclonal mGluR8/GIRK/HEK cells stably expressing Kir3.1/3.2, the M4 muscarinic receptor and rat mGlu8a were cultured as described previously (Niswender et al., [@B36]). Polyclonal stable T-REx-HEK-293 cell lines expressing Kir2.3 and Kir7.1-M125R under the control of a tetracycline-inducible promoter were established essentially as described in detail elsewhere (Fallen et al., [@B12]; Lewis et al., [@B26]). Monoclonal Kir2.3 cell lines were isolated through limiting dilution in 384-well plates and testing for tetracycline-inducible Tl^+^ flux, as described below. Polyclonal Kir7.1-M125R cells were used in this study. The development of monoclonal C1 T-REx-HEK-293 cells expressing Kir1.1 (S44D) was described previously (Lewis et al., [@B26]). T-REx-HEK-293 lines were cultured in DMEM growth medium containing 10% FBS, 50 U/mL Penicillin, 50 μg/mL Streptomycin, 5 μg/mL Blasticidin S, and 250 μg/mL Hygromycin.

Two-electrode voltage-clamp analysis
------------------------------------

Stage V--VI oocytes were isolated from gravid *Xenopus laevis* frogs using sterile surgical techniques under tricaine anesthesia. All methods were in accordance with the guidelines for the use of laboratory animals of Vanderbilt University School of Medicine. The oocyte follicle layer was removed by manual dissection following enzymatic treatment with 1 mg/mL collagenase (Type 1A Sigma) dissolved in calcium-free OR-2 of the following composition (in mM): 82.5 NaCl, 2 KCl, 1 MgCl~2~, 5 HEPES, with pH 7.5 adjusted with NaOH. Oocytes were allowed to recover overnight at 16°C in modified L-15 media containing gentamicin sulfate (25 mg/mL).

pcDNA3.1(+) vectors carrying Kir1.1, human Kir2.1, 2.3, and 7.1 cDNA were used to synthesize channel cRNA from a T7 RNA polymerase and nucleotides provided in the mMESSAGE mMACHINE kit (Ambion, Austin, TX, USA) after linearization of the expression constructs. cRNA was purified by LiCl precipitation, diluted in RNAase-free water and used for injections. The oocytes were injected with 0.5--10 ng of cRNA of Kir1.1, Kir2.1, Kir2.3, and Kir7.1 using a Drummond digital microdispenser. Oocytes were incubated at 16°C in modified L-15 for 24--72 h prior to Kir channel recordings.

Whole-cell currents were recorded from *Xenopus* oocytes injected with Kir channel cRNA using the two-electrode voltage-clamp (TEVC) technique. Current and voltage commands were generated with a GeneClamp 600 amplifier, a Digidata 1200 A/D converter, and pCLAMP 8.0 software (Molecular Devices, Sunnyvale, CA, USA). The bath was actively clamped to 0 mV using a VG-2A bath clamp (Molecular Devices). Electrodes pulled from borosilicate glass (Sutter Instruments, Novato, CA, USA) using a PP-830 vertical puller (Narishige International, Narishige, Japan) had resistances of 0.5--5.0 MΩ when filled with 3 M KCl. The standard bath solution contained (in mM): 85 NaCl, 5 KCl, 10 HEPES, 2 MgCl~2~, pH 7.4 with NaOH. After achieving stable current amplitude, VU573 was applied continuously. This was followed by application of the non-specific potassium channel blocker barium. For Kir current recordings, cells were voltage-clamped and stepped every 5 s from a holding potential of −70 to −100 mV for 200 ms, then ramped at a rate of 1.6 mV/ms to 60 mV before returning to −80 mV. All recordings were made at room temperature (20--23°C).

Whole-cell patch clamp electrophysiology
----------------------------------------

T-REx-HEK-293-Kir2.3 cells were patch clamped after overnight induction with tetracycline (1 μg/mL). GIRK (Kir3.1/3.2) and wild type Kir7.1 were studied in HEK-293 cells transiently co-transfected with the respective channel expression vectors and pcDNA3.1-EGFP (transfection marker) using Lipofectamine LTX/Plus reagent according to manufacturer's protocol (Invitrogen, Carlsbad, CA, USA). The standard intracellular solution contained 135 mM KCl, 2 mM MgCl~2~, 1 mM EGTA, 10 mM HEPES-free acid, and 2 mM Na~2~ ATP (Roche), pH 7.3, adjusted to 275 mOsmol/kg with sucrose. For Kir2.3 recordings, MgCl~2~ was reduced to 1 mM to prevent channel rundown (Chuang et al., [@B6]). The standard bath solution contained 135 mM NaCl, 5 mM KCl, 2 mM CaCl~2~, 1 mM MgCl~2~, 5 mM glucose, and 10 mM HEPES-free acid, pH 7.4, 290 mOsmol/kg. In some experiments, a high-K^+^ bath was used that contained 90 mM NaCl, 50 mM KCl, 2 mM CaCl~2~, 1 mM MgCl~2~, 5 mM glucose, and 10 mM HEPES-free acid, pH 7.4, 290 mM mOsmol/kg. Kir current recordings were collected as previously described (Bhave et al., [@B1]). After achieving stable whole-cell currents, VU573 was applied intermittently or continuously for 2--10 min, followed by application of 2 mM BaCl~2~. Data acquisition and analysis were performed using pClamp 9.2 software (Molecular Devices). All recordings were made at room temperature (20--23°C).

Test compound and stimulus plate preparation
--------------------------------------------

Compound master antagonist plates were created by serial diluting compounds 1:3 from 10 mM stock in 100% DMSO using the BRAVO liquid handler (Agilent Technologies, Santa Clara, CA, USA). Assay daughter plates were created using the ECHO 555 liquid hander (Labcyte, Sunnyvale, CA, USA), transferring 240 nL from the master plate to the daughter plate for each well followed by addition of 40 μL of assay buffer resulting in antagonist compound concentration--response curves (CRC) starting at 60 μM (2× final concentration). Glutamate was diluted in Tl^+^ buffer \[125 mM sodium bicarbonate (added fresh the morning of the experiment), 1 mM magnesium sulfate, 1.8 mM calcium sulfate, 5 mM glucose, 12 mM Tl^+^ sulfate, and 10 mM HEPES, pH 7.3\] at 5× the final concentration to be assayed.

Kinetic imaging, data analysis, and statistics
----------------------------------------------

Cells were loaded with the Tl^+^ sensitive fluorescent dye FluoZin-2 and plated in clear-bottom 384-well plates essentially as described previously (Lewis et al., [@B26]; Bhave et al., [@B1]). Cell plates and daughter compound plates were loaded onto a kinetic imaging plate reader (FDSS 6000; Hamamatsu Corporation, Bridgewater, NJ, USA). All recordings were made at room temperature (20--23°C). Appropriate baseline readings were taken (10 images at 1 Hz; excitation, 470 ± 20 nm; emission, 540 ± 30 nm) and 20 μL test compounds were added followed by 50 images at 1 Hz additional baseline. Following a 20-min incubation period, baseline readings were taken for 30 s followed by addition of 10 μL Glutamate at an EC~80~ concentration. An additional 170 images were taken at 1 Hz. Glutamate EC~80~ concentration was determined the day of the assay.

Data were analyzed using Excel (Microsoft Corp, Redmond, WA, USA). Raw data were opened in Excel and each data point in a given trace was divided by the first data point from that trace (static ratio). For experiments in which antagonists were added, data were again normalized by dividing each point by the fluorescence value immediately before the glutamate addition to correct for any subtle differences in the baseline traces after the compound incubation period. The slope of the fluorescence increase beginning 5 s after Tl^+^/glutamate addition and ending 15 s after Tl^+^/glutamate addition was calculated. The data were then plotted in Prism software (GraphPad Software, San Diego, CA, USA) to generate CRC after correcting for the slope values determined for baseline waveforms generated in the presence of vehicle controls. Potencies were calculated from fits using a four-parameter logistic equation.

Chemical synthesis
------------------

### General

All NMR spectra were recorded on a 400-MHz AMX Bruker NMR spectrometer. ^1^H chemical shifts are reported in δ values in part per million downfield with the deuterated solvent as the internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), integration, coupling constant (Hz). Low resolution mass spectra were obtained on an Agilent 1200 series 6130 mass spectrometer with electrospray ionization. High-resolution mass spectra were recorded on a Waters Q-TOF API-US plus Acquity system with electrospray ionization. Analytical thin layer chromatography was performed on EM Reagent 0.25 mm silica gel 60-F plates. Samples were analyzed for ≥95% purity using LC-UV/Vis-MS. Analytical HPLC was performed on an Agilent 1200 series with UV detection at 214 and 254 nm along with ELSD detection. LC/MS: method 1 = J-Sphere80-C18, 3.0 mm × 50 mm, 4.1 min gradient, 5%\[0.05%TFA/CH~3~CN\]:95%\[0.05%TFA/H~2~O\] to 100%\[0.05%TFA/CH~3~CN\]; method 2 = Phenomenex-C18, 2.1 mm × 30 mm, 2 min gradient, 7%\[0.1%TFA/CH~3~CN\]:93%\[0.1%TFA/H~2~O\] to 100%\[0.1%TFA/CH~3~CN\]; method 3 = Phenomenex-C18, 2.1 mm × 30 mm, 1 min gradient, 7%\[0.1%TFA/CH~3~CN\]:93%\[0.1%TFA/H~2~O\] to 95%\[0.1%TFA/CH~3~CN\]. Preparative purification was performed on a custom HP1100 purification system (Leister et al., [@B25]) with collection triggered by mass detection. Solvents for extraction, washing, and chromatography were HPLC grade. All reagents were purchased from Aldrich Chemical Co. and were used without purification.

#### Reagents

Substituted phenols were purchased from various commercial sources, 2-Amino-1-benzylbenzimidazole and 2-Amino-1-methylbenzimidazole were purchased from Acros Organics. 1-(4-Chlorophenylmethyl)-2-aminobenzimidazole was made using published procedures (Caroti et al., [@B5]).

### General synthetic procedure

The desired phenol (2 mmol) was dissolved in 0.4 mL NaOH (5 M) and then treated with epichlorohydrin (0.32 mL, 3.7 mmol; Scheme [1](#FS1){ref-type="fig"}). The mixture was heated in a Biotage Initiator microwave reactor at 100°C for a 15-min period. The reaction was cooled to ambient temperature and diluted with dichloromethane. The aqueous layer was removed and the organic layer extracted with water. The mixture was dried and solvent removed under reduced pressure. The crude mixture was then treated with the desired 2-aminobenzimidazole (3 mL, 0.2 mmol, 0.7 M MeOH) dissolved in methanol Scheme [1](#FS1){ref-type="fig"}). The mixture was allowed to stir for 4 days at ambient temperature. The solvent was removed under reduced pressure and the residue was diluted with dichloromethane. The mixture was extracted with water, dried, and concentrated under reduced pressure. The crude was purified using reverse phase chromatography (C18, Acetonitrile/H~2~O 0.1% TFA).

![**Synthesis of theVU573 scaffold**.](fphar-02-00075-scheme001){#FS1}

![](fphar-02-00075-scheme002.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(*p*-tolyloxy)propan-2-ol (1). Purchased from ChemBridge.

![](fphar-02-00075-scheme003.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(2,4-dichlorophenoxy)propan-2-ol (2).

LCMS: Rt = 1.41 min., \>98%, m/z = 443 \[M + H\].

![](fphar-02-00075-scheme004.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(4-chlorophenoxy)propan-2-ol (3).

LCMS: Rt = 1.38 min., \>98%, m/z = 408 \[M + H\].

![](fphar-02-00075-scheme005.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(*m*-tolyloxy)propan-2-ol (4).

Purchased from InterBioScreen.

![](fphar-02-00075-scheme006.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-phenoxypropan-2-ol (5).

Purchased from ChemBridge.

![](fphar-02-00075-scheme007.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(*o*-tolyloxy)propan-2-ol (6).

Purchased from ChemBridge.

![](fphar-02-00075-scheme008.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(3,5-difluorophenoxy)propan-2-ol (7).

LCMS: Rt = 1.05 min., \>98%, m/z = 410 \[M + H\].

![](fphar-02-00075-scheme009.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(4-isopropylphenoxy)propan-2-ol (8).

LCMS: Rt = 1.14 min., \>98%, m/z = 416 \[M + H\].

![](fphar-02-00075-scheme010.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-morpholinopropan-2-ol (9).

LCMS: Rt = 0.67 min., \>98%, m/z = 367 \[M + H\].

![](fphar-02-00075-scheme011.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(4-benzylphenoxy)propan-2-ol (10).

LCMS: Rt = 1.19 min., \>98%, m/z = 464 \[M + H\].

![](fphar-02-00075-scheme012.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(4-(benzyloxy)phenoxy)propan-2-ol (11).

LCMS: Rt = 1.16 min., \>98%, m/z = 480 \[M + H\].

![](fphar-02-00075-scheme013.jpg)

4-(3-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-2-hydroxypropoxy)benzonitrile (12).

LCMS: Rt = 1.00 min., \>98%, m/z = 399 \[M + H\].

![](fphar-02-00075-scheme014.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(4-methoxyphenoxy)propan-2-ol (13).

LCMS: Rt = 1.00 min., \>98%, m/z = 404 \[M + H\].

![](fphar-02-00075-scheme015.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(3-methoxyphenoxy)propan-2-ol (14).

LCMS: Rt = 1.01 min., \>98%, m/z = 404 \[M + H\].

![](fphar-02-00075-scheme016.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(2-chlorophenoxy)propan-2-ol (15).

LCMS: Rt = 1.08 min., 90%, m/z = 408 \[M + H\].

![](fphar-02-00075-scheme017.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(4-bromo-3-methylphenoxy)propan-2-ol (16).

LCMS: Rt = 1.13 min., \>98%, m/z = 466 \[M + H\].

![](fphar-02-00075-scheme018.jpg)

3-(3-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-2-hydroxypropoxy)-4-fluorobenzonitrile (17).

LCMS: Rt = 0.99 min., \>98%, m/z = 417 \[M + H\].

![](fphar-02-00075-scheme019.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(3-chlorophenoxy)propan-2-ol (18).

LCMS: Rt = 1.06 min., \>98%, m/z = 408 \[M + H\].

![](fphar-02-00075-scheme020.jpg)

3-(3-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-2-hydroxypropoxy)-5-fluorobenzonitrile (19).

LCMS: Rt = 1.00 min., 90%, m/z = 417 \[M + H\].

![](fphar-02-00075-scheme021.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(3,5-dimethylphenoxy)propan-2-ol (20).

LCMS: Rt = 1.10 min., 93%, m/z = 402 \[M + H\].

![](fphar-02-00075-scheme022.jpg)

1-(3-benzyl-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(2-methoxyphenoxy)propan-2-ol (21).

LCMS: Rt = 0.98 min., \>98%, m/z = 404 \[M + H\].

![](fphar-02-00075-scheme023.jpg)

1-(3-(4-chlorobenzyl)-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-phenoxypropan-2-ol (22).

LCMS: Rt = 1.33 min., 87%, m/z = 408 \[M + H\].

![](fphar-02-00075-scheme024.jpg)

1-(3-(4-chlorobenzyl)-2-imino-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(4-chlorophenoxy)propan-2-ol (23).

LCMS: Rt = 1.38 min., \>98%, m/z = 442 \[M + H\].

![](fphar-02-00075-scheme025.jpg)

1-(2-imino-3-(3-methoxybenzyl)-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(*p*-tolyloxy)propan-2-ol (24).

LCMS: Rt = 1.05 min., \>98%, m/z = 418 \[M + H\].

![](fphar-02-00075-scheme026.jpg)

1-(2-imino-3-methyl-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(*p*-tolyloxy)propan-2-ol (25).

LCMS: Rt = 0.91 min., \>98%, m/z = 312 \[M + H\].

![](fphar-02-00075-scheme027.jpg)

1-(2-imino-3-methyl-2,3-dihydro-1*H*-benzo\[d\]imidazol-1-yl)-3-(4-(trifluoromethyl)phenoxy)propan-2-ol (26).

LCMS: Rt = 1.11 min., \>98%, m/z = 442 \[M + H\].

Results
=======

VU573: A weak Kir1.1 inhibitor that preferentially inhibits GIRK
----------------------------------------------------------------

We recently performed a high-throughput screen (HTS) for small-molecule modulators of Kir1.1 (Lewis et al., [@B26]), the founding member of the inward rectifier potassium (Kir) channel family (Ho et al., [@B18]; Zhou et al., [@B58]) and putative diuretic target (Simon et al., [@B46]; Ji et al., [@B20]; Pasternak et al., [@B38]). A focused library of reproducibly active inhibitors was assembled from the primary screen, with the goal of mining the library for antagonists of other inward rectifiers. As noted in the Introduction, a growing body of evidence suggests that GIRK channels expressed in atrial cardiomyocytes may represent a viable drug target for the treatment of atrial fibrillation. Given the paucity of potent and selective small-molecule inhibitors of GIRK and therapeutic interest in the channel, we screened the focus library for GIRK modulators using a Tl^+^ flux-based fluorescence assay developed recently at Vanderbilt (Niswender et al., [@B36]). The assay reports Tl^+^ flux through heteromeric Kir3.1/3.2 channels co-expressed in HEK-293 cells with the group III metabotropic glutamate receptor mGluR8. Intracellular Tl^+^ concentration is reported using the commercially available Tl^+^-sensitive fluorescent dye FluoZin-2. As shown in Figure [1](#F1){ref-type="fig"}A, glutamate addition dose-dependently increased Tl^+^ flux as GIRK channels are activated by mGluR8 stimulation. The focused library was screened at a single concentration of 10 μM using an 80% maximally effective concentration (EC~80~) of glutamate. Several compounds were identified that preferentially inhibited GIRK over Kir1.1 (data not shown). One of these compounds, termed VU573, was selected for further study.

![**VU573 inhibits mGluR8-activated Kir3.1/3.2 channel activity in thallium flux assays**. **(A)** Representative FluoZin-2 fluorescence traces recorded from HEK-293 cells stably expressing mGluR8 and Kir3.1/3.2 before and after co-application of thallium and different doses of glutamate (shaded box). From an 11-point glutamate concentration--response curve (not shown), the glutamate concentration evoking approximately 80% (EC~80~) of the maximal response (EC~max~) was determined and used for subsequent experiments. **(B)** Representative traces for changes of Tl^+^-induced FluoZin-2 fluorescence following 20 min pre-treatment of cells with the indicated concentrations of VU573 and subsequent thallium and glutamate-EC~80~ addition (shaded box). **(C)** Mean ± SEM concentration--response curve for VU573-dependent inhibition of Kir3.1/3.2 (*n* = 3). The chemical structure of VU573 is shown in the inset. **(D)** Representative FluoZin-2 fluorescence traces recorded from monoclonal Kir1.1-S44D expressing cells cultured overnight in absence (−Tet) or presence (+Tet) of Tetracycline. **(E)** Representative traces for changes of Tl^+^-induced FluoZin-2 fluorescence following pre-treatment of cells with the indicated concentrations of VU573 and then exposed to thallium (shaded box). **(F)** Mean ± SEM concentration--response curve for VU573-dependent inhibition of Kir1.1-S44D (*n* = 3).](fphar-02-00075-g001){#F1}

The chemical structure of VU573 is shown in the inset of Figure [1](#F1){ref-type="fig"}C. The potency of VU573 was evaluated in 11-point CRC using an EC~80~ of glutamate to activate GIRK. As shown in Figure [1](#F1){ref-type="fig"}B, VU573 inhibited GIRK-dependent Tl^+^ flux in a dose-dependent manner with a 50% inhibition concentration (IC~50~) of approximately 1.9 μM (Figure [1](#F1){ref-type="fig"}C).

To verify that VU573 is a more potent inhibitor of GIRK than Kir1.1, a full VU573 CRC was generated using an established Tl^+^ flux assay for Kir1.1 (Lewis et al., [@B26]; Bhave et al., [@B1]). The assay employs an inducible system in which Kir1.1 is expressed from a tetracycline-regulatable promoter. As shown in Figure [1](#F1){ref-type="fig"}D, extracellular Tl^+^ addition produced a dramatic increase in FluoZin-2 fluorescence in cells cultured with tetracycline, but not in uninduced cells. Thus, most of the Tl^+^ flux in tetracycline-induced cells occurs through Kir1.1. VU573 exhibited weak yet dose-dependent inhibition of Kir1.1 (Figure [1](#F1){ref-type="fig"}F), with an IC~50~ of approximately 19 μM. Whole-cell patch clamp experiments confirmed that 20 μM VU573 inhibited Kir1.1 by 49.5 ± 0.03% (*n* = 5). Thus, VU573 is a preferential inhibitor of GIRK over Kir1.1.

VU573 shows preference for Kir2.3, GIRK, and Kir7.1 over Kir1.1 and Kir2.1
--------------------------------------------------------------------------

To further assess the selectivity of VU573, several members of the Kir channel family were expressed in *Xenopus* oocytes and screened for VU573 sensitivity using the TEVC technique. We first tested whether VU573 discriminates between Kir3.1/3.2 and Kir3.1/3.4 channels, the predominant heterotetrameric forms of GIRK found in the nervous system and heart, respectively (Hibino et al., [@B17]). Figure [2](#F2){ref-type="fig"}A illustrates a typical experiment performed on an oocyte co-injected with cRNA encoding Kir3.1 and Kir3.2. Current recorded at −80 mV is shown as a function of time. The oocyte was initially bathed in a potassium-free (0K) solution and then switched to one containing 90 mM K^+^ (90K) to activate GIRK. The dramatic increase in inward current in the presence of 90K buffer was not observed in water-injected oocytes (data not shown) and therefore largely reflects current through Kir3.1/3.2 channels. Bath application of 10 μM VU573 inhibited GIRK current by approximately 50%, which was significantly lower than expected from Tl^+^ flux experiments (Figure [1](#F1){ref-type="fig"}C). The residual current was blocked by Ba^2+^. Figure [2](#F2){ref-type="fig"}F shows mean ± SEM percentage block of Kir3.1/3.2 and Kir3.1/3.4 channels by 1, 10, and 25 μM VU573 or Ba^2+^. The mean ± SEM time constant (τ) for inhibition of Kir3.1/3.2 and Kir3.1/3.4 currents by 25 μM VU573 were 28 ± 4 s (*n* = 6) and 27 ± 5 s (*n* = 6), respectively. There were no significant (*P* \> 0.05) differences in the degree of VU573-dependent block of Kir3.1/3.2 and Kir3.1/3.4 channels at any of the concentrations.

![**Effect of VU573 on Kir channels expressed in oocytes**. **(A)** Representative Kir3.1/3.2 current traces recorded from an oocyte using the two-electrode voltage-clamp technique. Oocytes were initially bathed in a potassium-free (0K) solution and then switched to one containing 90 mM potassium (90K) to activate Kir3.1/3.2. After reaching a steady-state, the oocyte was exposed to 10 μM VU573 (in 90K) bath to inhibit Kir3.1/3.2. Residual Kir3.1/3.2 currents were inhibited with 2 mM barium (Ba^2+^). A final switch back to 0K was used to measure leak current at the end of each experiment. Representative whole-cell current traces recorded from oocytes expressing respectively **(B)** Kir1.1, **(C)** Kir2.1, **(D)** Kir2.3, and **(E)** Kir7.1 before and after application of 50 μM VU573. Residual Kir currents were inhibited with 2 mM barium (Ba^2+^). **(F)** Mean ± SEM percent inhibition of current evoked by Kir3.1/3.2, Kir3.1/3.4, Kir1.1, Kir2.1, Kir2.3, and Kir7.1 with the indicated concentrations of VU573 (![](fphar-02-00075-i034.jpg)) or Ba^2+^ (■) *n* = 4--6).](fphar-02-00075-g002){#F2}

GIRK channels are co-expressed with other members of the Kir channel family in a tissue- and cell type-specific manner. As noted in the Introduction, there is growing evidence that inhibitors of cardiac GIRK channels may be therapeutically beneficial in patients with atrial fibrillation. However, Kir2.1 and Kir2.3 are also expressed in the heart (Hibino et al., [@B17]) and therefore represent potential off-targets for VU573 actions. GIRK, Kir2.1, and Kir2.3 are also co-expressed in various brain regions, as is one of the newest Kir channel family members, Kir7.1 (Krapivinsky et al., [@B24]). We therefore determined whether VU573 inhibits any of these channels expressed in *Xenopus* oocytes. Kir1.1 was also expressed to confirm the results from Tl^+^ flux and patch clamp experiments.

Representative TEVC recordings from oocytes expressing Kir1.1, Kir2.1, Kir2.3, or Kir7.1 are shown in Figures [2](#F2){ref-type="fig"}B--E. The oocytes were voltage-clamped at −75 mV and stepped for 200 ms every 5 s to −120 mV to evoke inward current. The current amplitude at −120 mV is shown as a function of time. Barium was again used at the end of each experiment as a control blocker. Consistent with the Tl^+^ flux data showing greater potency toward GIRK than Kir1.1, 50 μM VU573 inhibited Kir1.1 by only 4.3 ± 1.7% with a time constant of 95 ± 15 s (*n* = 8). Kir2.1 was also relatively insensitive to VU573, and the time constant was very slow (τ = 735 ± 85 s; *n* = 4; Figure [2](#F2){ref-type="fig"}C). After 25 min of constant bath perfusion, 50 μM VU573 inhibited Kir2.1 by only 30.2 ± 9.4%. In contrast, Kir2.3 was inhibited comparatively quickly (τ  = 154 ± 32 s) by 80.9 ± 5.0% (*n* = 7). Similarly, Kir7.1 was inhibited by 66.0 ± 6% with a rapid time constant of 38 ± 6 s (*n* = 8).

Patch clamp analysis of VU573 potency in mammalian cells
--------------------------------------------------------

GIRK is inhibited by VU573 with an IC~50~ of approximately 2 μM in Tl^+^ flux assays in HEK-293 (Figure [1](#F1){ref-type="fig"}) cells and 10 μM in TEVC experiments in oocytes (Figure [2](#F2){ref-type="fig"}). To determine if the discrepancy is due to the expression system or assay type, whole-cell patch clamp techniques were used to assess the potency of VU573 toward Kir3.1/3.2 GIRK channels expressed in HEK-293 cells. The cells were voltage-clamped at a holding potential of −75 mV and then stepped to −120 mV for 200 ms, after which the membrane potential was ramped between −120 and 120 mV at a rate of 2.4 mV/ms. As shown in Figure [3](#F3){ref-type="fig"}B, GIRK activity was low in the presence of 5 mM extracellular K^+^ (5K), but increased upon elevation of bath K^+^ to 50 mM (50K), paralleling the behavior of GIRK observed in oocytes. Consistent with Tl^+^ flux data (Figure [1](#F1){ref-type="fig"}C), bath application of 30 μM VU573 led to a near complete inhibition of GIRK. As shown in the voltage ramp experiments in Figure [3](#F3){ref-type="fig"}A, VU573 inhibited GIRK across all potentials tested. The residual current was inhibited by barium (Ba^2+^; Figure [3](#F3){ref-type="fig"}B). The mean ± SEM time constant of inhibition was 16 ± 1 s (*n* = 5). A fit of the CRC data (Figure [3](#F3){ref-type="fig"}C) from patch clamp experiments yielded an IC~50~ of 1.3 μM, which is very near that derived from Tl^+^ flux assays (Figure [1](#F1){ref-type="fig"}C).

![**VU573-dependent inhibition of Kir3.1/3.2, Kir2.3, and Kir7.1 channel activity expressed in HEK-293 cells**. **(A,D,G)** Representative whole-cell Kir3.1/3.2, Kir2.3, and Kir7.1 current traces recorded from transfected HEK-293 cells. The cell was voltage ramped every 5 s between −120 and 120 mV for 200 ms from a holding potential of −75 mV. Normalized Kir3.1/3.2, Kir2.3, and Kir7.1 currents recorded before (black line) and after reaching steady-state inhibition by 30 μM VU573 (gray line) are shown. **(B,E,H)** Representative time course traces of VU573-dependent inhibition of Kir3.1/3.2, Kir2.3, and Kir7.1 by 30 μM VU573 using the protocol described above. After achieving whole-cell access, the current was allowed to stabilize before adding 30 μM VU573 and then 2 mM barium (Ba^2+^) to inhibit channel activity. **(C,F,I)** Mean ± SEM concentration--response curves for Kir3.1/3.2 (*n* = 4--7), Kir2.3 (*n* = 4--6), and Kir7.1 (*n* = 4--7), respectively.](fphar-02-00075-g003){#F3}

We extended our patch clamp experiments to include Kir2.3 and Kir7.1 due to their strong inhibition by VU573 in oocytes (Figure [2](#F2){ref-type="fig"}F). A monoclonal stable T-REx-HEK-293 cell line expressing Kir2.3 under the control of a tetracycline-inducible promoter was patch clamped following overnight induction with tetracycline. Kir7.1 was studied in transiently transfected HEK-293 cells (see [Materials and Methods](#s1){ref-type="sec"}). The cells were subjected to the same voltage ramp protocol described above for GIRK. Steady-state Kir2.3 and Kir7.1 currents recorded before (black line) and after (gray line) bath application of 30 μM VU573 are shown in Figures [3](#F3){ref-type="fig"}D,G, respectively. Both channels were inhibited with a rapid time course (Figures [3](#F3){ref-type="fig"}E,H) and IC~50~ values of approximately 1 μM (Figures [3](#F3){ref-type="fig"}F,I). The mean ± SEM time constants for inhibition of Kir2.3 and Kir7.1 were 23 ± 2 and 14 ± 2 s, respectively (*n* = 4 each).

Development of Tl^+^ flux assays for Kir2.3 and Kir7.1-M125R
------------------------------------------------------------

We next set out to employ medicinal chemistry in an effort to improve the potency and selectivity of VU573 toward GIRK, Kir2.3, and Kir7.1. Conventional electrophysiological methods are too slow and labor intensive to support a robust medicinal chemistry campaign, leading us to establish high-throughput Tl^+^ flux assays for Kir2.3 and Kir7.1.As shown in Figure [4](#F4){ref-type="fig"}A, robust tetracycline-inducible Tl^+^ flux was observed in monoclonal stable T-REx-HEK-293 expressing Kir2.3. VU573 dose-dependently inhibited Tl^+^ flux through Kir2.3 with an IC~50~ of 4.7 μM (Figures [4](#F4){ref-type="fig"}B,C), a value that is reasonably close to that derived from patch clamp experiments (Figure [3](#F3){ref-type="fig"}F).

![**Development of a thallium flux assay for Kir2.3**. **(A)** Thallium flux-dependent FluoZin-2 fluorescence recorded from monoclonal Kir2.3 T-REx-HEK-293 cells cultured overnight in absence (−Tet) or presence (+Tet) of Tetracycline. The fluorescence emission was recorded before and after the addition of extracellular thallium (shaded box). **(B)** Representative traces for changes of Tl^+^-induced FluoZin-2 fluorescence following 20 min pre-treatment of cells with the indicated concentrations of VU573. **(C)** CRC for VU573-dependent inhibition of Kir2.3 activity. Values are mean ± SEM (*n* = 3). A fit of the CRC with a single-site four-parameter logistic function yielded IC~50~ of 4.7.](fphar-02-00075-g004){#F4}

In contrast, despite numerous attempts on multiple polyclonal and monoclonal cell lines, we were unable to detect Tl^+^ flux through Kir7.1. Western blot analysis revealed that this was not due to lack of channel protein expression (data not shown), suggesting that other channel properties were responsible. Kir7.1 is unique among Kir channels in that it has a very small unitary conductance, which has been estimated from noise analysis to be on the order of 50 femptoSiemens (fS; Krapivinsky et al., [@B24]). We reasoned that this could keep Tl^+^ flux through Kir7.1 below the limit of detection of FluoZin-2. The small conductance of the channel is due at least in part to a non-conserved Methionine (M) residue at position 125 located in the pore. Mutation of the residue to Arginine (R),which occupies the homologous position in all other Kir channels (not shown), has no effect on protein expression or targeting to the plasma membrane, but increases the single-channel conductance by approximately 20-fold (Krapivinsky et al., [@B24]). We therefore wondered if the M125R mutation could enable measurement of Tl^+^ flux using FluoZin-2. As shown in Figure [5](#F5){ref-type="fig"}B, tetracycline-induced robust Tl^+^ flux in polyclonal stable T-REx-HEK-293 cells expressing Kir7.1-M125R. VU573 induced concentration-dependent inhibition of Tl^+^ flux with an IC~50~ of 4.9 μM (Figures [5](#F5){ref-type="fig"}C,D). The good correlation between IC~50~ values from patch clamp and Tl^+^ flux experiments and the fact that the M125R mutation had no effect on the sensitivity to VU573 in patch clamp experiments (Figure [5](#F5){ref-type="fig"}A) indicated that the Kir7.1-M125R assays could be used as a screening tool to support medicinal chemistry efforts for VU573.

![**Development of a thallium flux assay for Kir7.1 (M125R)**. **(A)** Mean ± SEM % inhibition of wild type (closed bars; *n* = 6--7) or M125R mutant (open bars; *n* = 4--6) Kir7.1 by the indicated concentration of VU573.Note that the wild type data are reproduced from Figure [3](#F3){ref-type="fig"}. **(B)** Thallium flux-dependent FluoZin-2 fluorescence recorded from polyclonalKir7.1 (M125R) T-REx-HEK-293 cells cultured overnight in absence (−Tet) or presence (+Tet) of Tetracycline. The fluorescence emission was recorded before and after the addition of extracellular thallium (shaded box). **(C)** Representative traces for changes of Tl^+^-induced FluoZin-2 fluorescence following 20 min pre-treatment of cells with the indicated concentrations of VU573. **(D)** CRC for VU573-dependent inhibition of Kir2.3 activity. Values are mean ± SEM (*n* = 3). A fit of the CRC with a single-site four-parameter logistic function yielded IC~50~ of 4.9 μM.](fphar-02-00075-g005){#F5}

Synthesis and structure--activity relationships of VU573 analogs
----------------------------------------------------------------

Lead optimization efforts directed at VU573 to improve its potency and selectivity toward Kir2.3, GIRK, and Kir7.1 were initiated by conserving the benzyl moiety and substituting the R group (Table [1](#T1){ref-type="table"}). Structure--activity relationships (SAR) revealed few analogs with channel selectivity. Replacement of the phenoxy moiety with a morpholino group to the VU573 scaffold resulted in compound (9), which lost activity (IC~50~ values \> 100 μM) for Kir7.1 and Kir1.1. The IC~50~ values for Kir2.3 and GIRK were 24 and 15.3 μM, respectively. Substitution of the R group of the VU573 scaffold with a phenoxy benzyloxy functional group led to an analog (11), which was equipotent for Kir2.3 and GIRK, but loss activity toward Kir7.1 (IC~50~ values \> 100 μM). An alternate functional group for the VU573 scaffold, a 4-cyanophenyl (12), led to an analog compound with moderate selectivity for GIRK (IC~50~ = 5.27 μM) and weak inhibition of Kir2.3 and Kir7.1, with IC~50~ values of 11.3 and 19.7 μM, respectively. All other analogs in which substitutions were made at both R and R′ groups led to similar potency among the Kir2.3, Kir7.1, and GIRK channels as compared to VU573, but with weak inhibition for Kir1.1. The development of two VU573 analogs, R70 and R5C (Table [1](#T1){ref-type="table"}), that retain activity toward GIRK and Kir2.3 but have lost activity toward Kir7.1 suggest that chemically optimized analogs based on the VU573 scaffold can be developed to increase their selectivity.

###### 

**Structure--activity relationships and lead optimization summary**.

  ![](fphar-02-00075-i001.jpg)                                                                                                                                  
  ------------------------------ ------------------------------ ------------------------------ ------------------ ----------------- ------------- ------------- -------------
  1                              ![](fphar-02-00075-i002.jpg)                                  VU0160573-1/IC4X   4.15 ± 0.35       4.77 ± 2.89   2.17 ± 0.40   10.8 ± 3.8
  2                              ![](fphar-02-00075-i003.jpg)                                  VU0403134-1/IC3Y   5.33 ± 2.08       4.73 ± 2.57   3.20 ± 0.71   7.07 ± 2.30
  3                              ![](fphar-02-00075-i004.jpg)                                  VU0403131-1/IC58   4.20 ± 1.25       5.17 ± 1.89   2.90 ± 1.10   6.57 ± 3.80
  4                              ![](fphar-02-00075-i005.jpg)                                  VU0340260-1/IC38   7.53 ± 2.34       8.00 ± 3.86   4.95 ± 1.80   11.2 ± 2.8
  5                              ![](fphar-02-00075-i006.jpg)                                  VU0026784-1/IC3L   3.43 ± 0.67       4.47 ± 2.40   1.95 ± 0.49   11.7 ± 4.1
  6                              ![](fphar-02-00075-i007.jpg)                                  VU0288495-1/IC39   5.33 ± 1.70       4.10 ± 1.93   1.95 ± 0.07   11.9 ± 2.2
  7                              ![](fphar-02-00075-i008.jpg)                                  VU0451348-1/R6P    3.53 ± 1.33       4.20 ± 0.95   1.40 ± 0.35   7.57 ± 2.20
  8                              ![](fphar-02-00075-i009.jpg)                                  VU0451344-1/R80    5.03 ± 1.96       6.03 ± 1.60   3.37 ± 0.70   6.77 ± 1.70
  9                              ![](fphar-02-00075-i010.jpg)                                  VU0451342-1/R70    24.0 ± 10.4       \>100         15.3 ± 0.6    \>100
  10                             ![](fphar-02-00075-i011.jpg)                                  VU0451341-1/R7M    2.80 ± 0.99       6.07 ± 2.71   3.83 ± 1.10   6.13 ± 0.23
  11                             ![](fphar-02-00075-i012.jpg)                                  VU0451340-1/R5C    2.33 ± 0.68       \>100         3.17 ± 0.86   5.23 ± 0.59
  12                             ![](fphar-02-00075-i013.jpg)                                  VU0451339-1/R56    11.3 ± 1.2        19.7 ± 7.4    5.27 ± 0.40   15.7 ± 2.1
  13                             ![](fphar-02-00075-i014.jpg)                                  VU0066224-6/R7N    3.87 ± 1.40       6.70 ± 1.39   1.50 ± 0.44   12.7 ± 1.2
  14                             ![](fphar-02-00075-i015.jpg)                                  VU0451336-1/R5B    3.13 ± 1.45       3.47 ± 0.67   1.43 ± 0.25   10.1 ± 2.9
  15                             ![](fphar-02-00075-i016.jpg)                                  VU0451333-1/R5X    4.95 ± 1.34       5.33 ± 2.91   2.77 ± 0.60   8.60 ± 1.20
  16                             ![](fphar-02-00075-i017.jpg)                                  VU0451337-1/R5K    5.10 ± 1.27       6.10 ± 3.12   3.43 ± 0.21   8.53 ± 1.70
  17                             ![](fphar-02-00075-i018.jpg)                                  VU0451332-1/R7B    5.30 ± 1.56       4.33 ± 1.33   1.40 ± 0.30   8.27 ± 0.29
  18                             ![](fphar-02-00075-i019.jpg)                                  VU0451338-1/R71    4.45 ± 0.92       5.63 ± 2.24   2.83 ± 0.42   11.7 ± 2.1
  19                             ![](fphar-02-00075-i020.jpg)                                  VU0451330-1/R6J    7.15 ± 0.71       8.27 ± 2.37   1.93 ± 0.21   14.3 ± 1.5
  20                             ![](fphar-02-00075-i021.jpg)                                  VU0451331-1/RKN    3.65 ± 0.21       3.03 ± 0.68   4.33 ± 0.68   16.0 ± 2.0
  21                             ![](fphar-02-00075-i022.jpg)                                  VU0451846-2/R87    3.60 ± 0.28       8.50 ± 2.18   5.13 ± 1.60   19.3 ± 1.5
  ![](fphar-02-00075-i023.jpg)                                                                                                                                  
  **Cmpd**                       **R**                          **R′**                         **VU\#/Barcode**   **IC~50~ (μM)**                               
                                                                                                                  **Kir2.3**        **Kir7.1**    **GIRK**      **Kir1.1**
  22                             ![](fphar-02-00075-i024.jpg)   ![](fphar-02-00075-i029.jpg)   VU0401333-1/IC4L   7.20 ± 1.73       8.93 ± 3.53   4.80 ± 1.10   14.7 ± 2.1
  23                             ![](fphar-02-00075-i025.jpg)   ![](fphar-02-00075-i030.jpg)   VU0403132-1/IC48   5.70 ± 3.18       19.5 ± 28.2   3.35 ± 0.92   6.53 ± 3.90
  24                             ![](fphar-02-00075-i026.jpg)   ![](fphar-02-00075-i031.jpg)   VU0451343-1/RJ4    2.80 ± 0.89       3.00 ± 0.87   4.20 ± 0.69   13.7 ± 4.4
  25                             ![](fphar-02-00075-i027.jpg)   ![](fphar-02-00075-i032.jpg)   VU0451335-1/R5P    16.5 ± 0.7        25.3 ± 8.5    12.3 ± 2.5    13.0 ± 2.6
  26                             ![](fphar-02-00075-i028.jpg)   ![](fphar-02-00075-i033.jpg)   VU0451334-1/R7L    4.90 ± 0.14       5.20 ± 1.82   2.87 ± 0.31   6.97 ± 2.00

*Summary of structure--activity relationships of VU573 analogs. Reported IC~50~ values were measured by Tl^+^ flux assay. Values are mean ± SEM (*n* = 3)*.

To determine if the apparent loss of activity is an artifact of the Tl^+^ flux assay or the use of the M125R mutant, we examined the effects of the VU573 analog R70 on wild type Kir7.1 currents in whole-cell patch clamp experiments. The cells were voltage-clamped between −120 and 120 mV in 20 mV increments from a −75-mV holding potential (Figure [6](#F6){ref-type="fig"}E). As illustrated in the average current traces recorded before (Figure [6](#F6){ref-type="fig"}A) or during bath application of 10 μM R70 (Figure [6](#F6){ref-type="fig"}B), the analog had no effect on wild typeKir7.1 activity. In contrast, subsequent addition of 10 μM VU573 led to a near complete inhibition of the channel (Figures [6](#F6){ref-type="fig"}C). The mean ± SEM current--voltage relationships recorded in the three conditions are shown in Figure [6](#F6){ref-type="fig"}D.

![**Lack of effect of R70 on wild type Kir7.1 activity**. Average Kir7.1 current traces (*n* = 4 each) recorded in the absence **(A)** or presence of **(B)** 10 μM R70 or **(C)** 10 μM VU573. **(D)** Mean ± SEM (*n* = 4) current--voltage Kir7.1 relationships recorded in the indicated conditions using the voltage-clamp protocol shown in **(E)**.](fphar-02-00075-g006){#F6}

Discussion
==========

The Tl^+^ flux assay developed by Weaver et al. ([@B54]) and subsequently commercialized by Invitrogen under the FluxOR© label has had a major impact on high-throughput screening for potassium channels. The assay takes advantage of the fact that Tl^+^ readily permeates most K^+^ channel pores. With the exception of wild type Kir7.1, the assay seems to be particularly well suited for inward rectifier K^+^ channels due to their high open probability near the resting membrane potential of a cell. This obviates the need for depolarizing the cell with a high-potassium step to open voltage-gated K^+^ channels. To date, Tl^+^ flux assays have been reported for the inward rectifiers Kir1.1 (Lewis et al., [@B26]), Kir2.1 (Wang et al., [@B53]), Kir2.3 (this study), Kir3.1/3.2 (Niswender et al., [@B36]), and Kir7.1-M125R (this study). Tl^+^ flux assays have also been developed for some ligand- and voltage-gated potassium channels, including SK3 and KCNQ2 (Weaver et al., [@B54]), KCNQ4 (Li et al., [@B27]), and hERG (Titus et al., [@B49]; Bridal et al., [@B3]; Huang et al., [@B19]; Schmalhofer et al., [@B44]; Zou et al., [@B59]). A Tl^+^ flux assay was used to screen for modulators of the potassium-chloride co-transporter KCC2 (Delpire et al., [@B9]). This is notable because KCC2 is electroneutral and therefore cannot be screened using voltage-sensitive dyes. Thus, the Tl^+^ flux assay appears to be broadly adaptable to both electrogenic and electroneutral K^+^ transport proteins.

In the present study, Tl^+^ flux- and electrophysiological-based counterscreens revealed a preferential inhibitor of GIRK, Kir2.3, and Kir7.1. It is unclear why IC~50~ values are lower in oocytes compared to mammalian cells, but likely reflects differences in membrane properties or intracellular factors between the two cell types. VU573 inhibits GIRK independent of GPCR stimulation and does not discriminate between cardiac (Kir3.1/3.4) and neuronal (Kir3.1/3.2) forms of the channel. The latter observation suggests that the VU573 binding site is located within the Kir3.1 subunit, which is common to both heteromeric forms, or is shared between all three subunits. Pharmacology experiments on homotetrameric Kir3.1, Kir3.2, and Kir3.4 channels should help resolve the issue. Given the broad tissue distribution and important physiological functions of GIRK channels in multiple organ systems, the development of subtype selective modulators may be important for developing, for example, cardiac-specific drugs to treat atrial fibrillation without toxic side effects on the nervous system. The availability of high-resolution crystal structures of the GIRK cytoplasmic domain (Nishida and Mackinnon, [@B35]), GIRK-bacterial Kir channel chimeras (Nishida et al., [@B34]) and now full-length mammalian Kir2.2 (Tao et al., [@B48]) should be helpful in guiding and interpreting experiments to define the molecular binding site for VU573 and other GIRK antagonists. The relatively flat SAR of VU573 against GIRK, Kir2.3, and Kir7.1 suggests that the VU573 scaffold may be amenable to the addition of diazirine or other light-reactive moieties for photoaffinity labeling of the channels for identification of the binding site using mass spectrometry. A detailed understanding of both unique and overlapping binding sites will provide novel insights into the molecular architecture of GIRK and should facilitate the development of subtype-specific inhibitors.

Members of the Kir2.X subfamily, including Kir2.1, Kir2.2, Kir2.3, Kir2.4, and Kir2.6, are broadly expressed in neurons, cardiac, skeletal and smooth muscle cells, endothelial cells, macrophages, and epithelial cells (De Boer et al., [@B7]). Much of our understanding of the physiology of Kir2.X channels comes from studies of disease-causing mutations in humans (Plaster et al., [@B39]; Ryan et al., [@B43]) and knockout mice (Zaritsky et al., [@B57]). While it is clear from this work that Kir2.X channels are essential in many organ systems, pinpointing their individual roles has been difficult due to their overlapping expression profiles, propensity to form Kir2.X heterotetramers and poorly developed pharmacology. The development of subtype selective Kir2.X inhibitors would undoubtedly bolster efforts to understand the physiology and druggability of Kir2.X homo- and heteromeric channels. To date, however, the inhibitor pharmacology of Kir2.X channels is limited to barium, cesium, and a handful of non-specific drugs such as chloroquine (Rodriguez-Menchaca et al., [@B42]), mefloquine (Lopez-Izquierdo et al., [@B29]), quinacrine (Lopez-Izquierdo et al., [@B28]), carvedilol (Ferrer et al., [@B13]), tamoxifen (Ponce-Balbuena et al., [@B40]), and pentamidine (De Boer et al., [@B8]). Pregnenolone sulfate (Kobayashi et al., [@B23]) and flecainide (Caballero et al., [@B4]) are activators of Kir2.3 and Kir2.1, respectively. Like VU573 (this study), mefloquine, quinacrine, tamoxifen, and carvedilol preferentially inhibit Kir2.3 over Kir2.1. Electrophysiological analysis of mutagenized channels suggests that chloroquine and pentamidine are cytoplasmic pore blockers, whereas mefloquine and carvedilol appear to disrupt channel interactions with the activating membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP~2~). There is evidence that quinacrine has a complex mechanism of action involving both pore block and disruption of channel-PIP~2~ interactions. Because VU573 is also a preferential inhibitor of Kir2.3, we are currently testing if it shares a common mechanism of action and binding site(s) with these drugs. Looking ahead, it will be important to determine whether VU573 or any of the aforementioned drugs show preference for homomeric versus heteromeric Kir2.X channels. These studies may help inform medicinal chemistry efforts to develop subtype-specific inhibitors of Kir2.X channels.

To our knowledge, VU573 is only the second and most potent Kir7.1 inhibitor available. We recently reported that the ∼300 nM Kir1.1 inhibitor 7,13-*bis*\[(4-nitrophenyl)methyl\]-1,4,10-trioxa-7,13-diazacyclopentadecanedihydrochloride, or VU590, inhibits Kir7.1 with an IC~50~ of approximately 8 μM, making VU590 the first publically disclosed small-molecule inhibitor of both Kir1.1 and Kir7.1 (Lewis et al., [@B26]). In the present study, we found that VU573 preferentially inhibits Kir7.1 (IC~50~ ∼ 1 μM) over Kir1.1 (IC~50~ ∼ 19 μM).

Kir7.1 is widely expressed in the brain, retinal pigment epithelial cells of the eye, the choroid plexus, and epithelial cells of the intestine, nephron, and inner ear (Krapivinsky et al., [@B24]; Nakamura et al., [@B33]; Ookata et al., [@B37]; Pondugula et al., [@B41]; Yang et al., [@B56]). Very little is known about the physiology of Kir7.1 due in part to the unusually small (i.e., ∼50 fS) unitary conductance of the channel. This precludes the use of single-channel recording techniques to study its activity in native cell types, where other inward rectifiers of larger unitary conductances are often co-expressed. Whole-cell patch clamp recordings could conceivably be used to dissect out the relative contributions of Kir7.1 and other Kir channels to the macroscopic current provided that specific blockers were available. This scenario highlights the need for better pharmacological modulators of Kir7.1 and other members of the Kir channel family. The discovery of VU573 and its inactive analogs represent important steps toward filling this gap. Furthermore, and importantly, the development of a robust Tl^+^ flux assay using the Kir7.1-M125R mutant will enable HTS for chemically diverse modulators of the channel.

Interestingly, heritable mutations in the Kir7.1-encoding gene *KCNJ13* were recently found in patients with two forms of retinal disease (Hejtmancik et al., [@B16]; Sergouniotis et al., [@B45]). These findings confirm the importance of Kir7.1 in retinal pigmented epithelia of the eye and raise questions regarding the detailed physiological roles of Kir7.1 in the eye and other organ systems. The development of potent and selective Kir7.1 antagonists will greatly facilitate those efforts.
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